T-0156

• Description :

  T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM) . T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM) . T-0156 enhances the nitric oxide (NO) /cGMP pathway[1].

• UNSPSC :

  12352005

• Target :

  Phosphodiesterase (PDE)

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/t-0156.html

• Solubility :

  10 mM in DMSO

• Smiles :

  COC(C(N1CC2=CC=NC(C)=C2)=C(C3=CC(OC)=C(OC)C(OC)=C3)C4=CC=NC(OCC5=NC=CC=N5)=C4C1=O)=O.Cl

• Molecular Formula :

  C31H30ClN5O7

• Molecular Weight :

  620.05

• References & Citations :

  [1]Hideki Mochida, et al. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2002 Dec 5;456 (1-3) :91-8.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PDE1; PDE2; PDE3; PDE4; PDE5; PDE6

• CAS Number :

  [324572-93-2]